AVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVR-RD-01 for the Treatment of Fabry Disease
19 déc. 2018 07h00 HE
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Dec. 19, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company developing gene therapies to potentially cure rare...
AVROBIO, Inc. Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
18 déc. 2018 07h05 HE
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company, today announced the grant of non-qualified stock...
AVROBIO, Inc. Expands and Strengthens Leadership Team with Four Senior Management Hires
18 déc. 2018 07h00 HE
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company, today announced the appointment of four key senior...
AVROBIO, Inc. Reports Third Quarter 2018 Financial Results and Provides Business Update
13 nov. 2018 08h00 HE
|
AVROBIO, Inc.
During the quarter, announced updated Fabry clinical data, acceptance of Clinical Trial Application for Gaucher, and continued platform optimization CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE...
AVROBIO, Inc. to Present at Chardan's 2nd Annual Genetic Medicines Conference
04 oct. 2018 16h01 HE
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Oct. 04, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company developing gene therapies to potentially cure rare...
AVROBIO Receives No Objection to Clinical Trial Application from Health Canada for AVR-RD-02 Gene Therapy for Gaucher Disease
01 oct. 2018 07h01 HE
|
AVROBIO, Inc.
Company plans to initiate Phase 1/2 clinical trial in patients with Gaucher disease in 2019 AVROBIO continues to advance its pipeline of gene therapies for lysosomal storage disorders CAMBRIDGE,...
AVROBIO Announces Updated Clinical Data for AVR-RD-01 Gene Therapy in Fabry Disease
01 oct. 2018 07h00 HE
|
AVROBIO, Inc.
First two patients in Phase 1 study continue to demonstrate AGA enzyme activity above the diagnostic range for classic Fabry disease 18 months and six months after receiving AVR-RD-01, respectively;...
AVROBIO, Inc. to Present at Upcoming Investor Conferences
28 août 2018 08h00 HE
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical stage gene therapy company focused on developing potentially curative...
AVROBIO, Inc. Reports Second Quarter 2018 Financial Results and Provides Business Update
09 août 2018 08h00 HE
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Aug. 09, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical stage gene therapy company focused on developing potentially curative...
AVROBIO, Inc. to Present at the 2018 Wedbush PacGrow Healthcare Conference
08 août 2018 08h00 HE
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical stage gene therapy company focused on developing potentially curative...